Biosimilars | Access & Reimbursement | US/EU5 | 2017
The success of biologics will greatly depend on payers because they are the ones who determine which products gain formulary access and preferential reimbursement. Understanding the factors that influence payer decisions regarding biosimilars, particularly their thinking behind reimbursement of recent additions to the market like Pfizer’s Inflectra (infliximab-dyyb) and Celltrion/Mundipharma’s Truxima (rituximab), is critical for successfully managing the launch and marketing of a novel biosimilar. This primary market research was designed to assess payers’ current experience with biosimilars and how they expect to manage biosimilars in the future.
Questions answered:
- What are payers’ perspectives on the drivers and barriers to biosimilar uptake?
- What factors influence which biosimilars are preferred on formularies in the U.S.?
- How do payers choose between multiple biosimilars of the same brand in the EU?
- What strategies do payers use to manage biosimilars?
- What expectations do payers have for biosimilar discounts?
- How would the availability of biosimilars influence the pricing of emerging agents?
- Will payer strategies for biosimilars differ between therapeutic specialties?
Key markets covered:
- France
- Germany
- Italy
- Spain
- United Kingdom
- United States
Key companies mentioned:
- Amgen
- Boehringer Ingelheim
- Celltrion
- Eli Lilly
- Hospira
- Janssen
- Johnson & Johnson
- Merck & Co.
- Mundipharma
- Mylan
- Novartis
- Pfizer
- Roche
- Samsung Bioepis
- Sandoz
- Sanofi
- Teva
Key drugs mentioned:
- Aranesp
- Avastin
- Basaglar
- Benepali
- Binocrit
- Enbrel
- Flixabi
- Genotropin
- Herceptin
- Humira
- Inflectra
- Lantus
- Neulasta
- Neupogen
- Nivestim
- Omnitrope
- Procrit/Epogen
- Remicade
- Remsima
- Rituxan/MabThera
- Truxima
- Zarzio/Zarxio
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
